Summary
"CroíValve is an innovative SME with the mission to lead the treatment of tricuspid valve disease and transform the lives of patients who currently face certain death.
In the US and EU, 550,000 patients present with tricuspid valve disease annually. Current treatment involves highly invasive, risky open-heart surgery and €2.5Bn/year. With H2020 SMEi funding, this Phase 2 Innovation Proposal will support the activities necessary to complete clinical trials and demonstrate safety and efficacy for CE Mark approval. Securing this grant, alongside private funding, will enable the company to expand its manufacturing capabilities, build up its sales and marketing infrastructure. CroíValve’s management team have a successful track record in the development, patenting and commercialisation of medical devices who can position the company as a leader in the treatment of tricuspid valve disease."
In the US and EU, 550,000 patients present with tricuspid valve disease annually. Current treatment involves highly invasive, risky open-heart surgery and €2.5Bn/year. With H2020 SMEi funding, this Phase 2 Innovation Proposal will support the activities necessary to complete clinical trials and demonstrate safety and efficacy for CE Mark approval. Securing this grant, alongside private funding, will enable the company to expand its manufacturing capabilities, build up its sales and marketing infrastructure. CroíValve’s management team have a successful track record in the development, patenting and commercialisation of medical devices who can position the company as a leader in the treatment of tricuspid valve disease."
Unfold all
/
Fold all
More information & hyperlinks
| Web resources: | https://cordis.europa.eu/project/id/872800 |
| Start date: | 01-10-2019 |
| End date: | 31-10-2022 |
| Total budget - Public funding: | 5 450 186,00 Euro - 2 494 970,00 Euro |
Cordis data
Original description
"CroíValve is an innovative SME with the mission to lead the treatment of tricuspid valve disease and transform the lives of patients who currently face certain death.In the US and EU, 550,000 patients present with tricuspid valve disease annually. Current treatment involves highly invasive, risky open-heart surgery and €2.5Bn/year. With H2020 SMEi funding, this Phase 2 Innovation Proposal will support the activities necessary to complete clinical trials and demonstrate safety and efficacy for CE Mark approval. Securing this grant, alongside private funding, will enable the company to expand its manufacturing capabilities, build up its sales and marketing infrastructure. CroíValve’s management team have a successful track record in the development, patenting and commercialisation of medical devices who can position the company as a leader in the treatment of tricuspid valve disease."
Status
CLOSEDCall topic
EIC-SMEInst-2018-2020Update Date
27-10-2022
Geographical location(s)
Structured mapping
Unfold all
/
Fold all
